ProCE Banner Activity

Key Decisions in HIV Care: Rapid Initiation of ART

Podcast Episodes
In this on-demand recording of a live webinar, expert faculty review key considerations for rapid initiation of ART. Topics include current recommendations and a discussion of the data to support ART options for rapid initiation.

Released: September 29, 2021

Expiration: September 28, 2022

No longer available for credit.

Share

Faculty

Jason Halperin

Jason Halperin, MD, MPH, FIDSA

Director of Specialty Program
DAP Health
Cathedral City, California

Jürgen K. Rockstroh

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Jason Halperin, MD, MPH, FIDSA

Director of Specialty Program
DAP Health
Cathedral City, California

Jason Halperin, MD, MPH, has no relevant conflict of interest to report.

Jürgen K. Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
University Hospital Bonn
Bonn, Germany  

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, Theratechnologies, and ViiV.